Press Enter to search · Esc to close
Semaglutide and liraglutide are being studied well past their metabolic origins. Early signals point to alcohol use disorder and diabetic blood-vessel protection — but the evidence is still uneven.
A 56-week randomized trial finally tests what patients and surgeons have been doing off-script: adding liraglutide when the scale starts climbing again after bypass.
A cluster of new 2025 papers reframes GLP-1 drugs as long-horizon metabolic tools — with real promise after bariatric surgery, a tantalizing brain-protection signal, and one safety question worth taking seriously.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
GLP-1 receptor agonists are sprawling past diabetes and obesity into cardiovascular protection, body-composition debates, and pill-form delivery. Here is what the latest wave of evidence supports — and what it doesn't.
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.